Tech Company Financing Transactions
Syantra Funding Round
Canaccord Genuity and private investors participated in a $3.2 million Series A capital raise for Syantra. The financing round was announced on 9/11/2024.
Transaction Overview
Company Name
Announced On
9/11/2024
Transaction Type
Venture Equity
Amount
$3,200,000
Round
Series A
Investors
Canaccord Genuity (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
105 - 32 Royal Vista Drive NW
Calgary, Alberta, T3R 0H9
Canada
Calgary, Alberta, T3R 0H9
Canada
Phone
Website
Email Address
Overview
Syantra Inc. is a privately held, precision biotechnology company that's changing the way cancer is detected and treated. Our flagship product, Syantra DX� Breast Cancer, is a screening blood test for the detection of breast cancer. It measures a panel of gene expression biomarkers from whole blood and then uses a software package, developed with machine learning, to interpret data and provide a result of positive or negative.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Rifat Pamukcu
Chief Executive Officer
Rob Lozuk
Chief Medical Officer
Randy Moore
Chief Operating Officer
Bob Shepherd
Chief Scientific Officer
Kristina Rinker
VP - Product Management
Kenneth Fuh
Browse more venture capital transactions:
Prev: 9/11/2024: Optalitix venture capital transaction
Next: 9/11/2024: Connectly.ai venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs